961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapyIván Márquez‐Rodas, Stéphane Dalle, Philippe Saïag et al.|Unknown|2021Cited by 8
Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 studyIván Márquez‐Rodas, Stéphane Dalle, Ana Arance et al.|Cancer Research|2022Cited by 6
Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel databaseJ.‐M. L'Orphelin, Brigitte Dréno, P. Celérier et al.|European Journal of Dermatology|2022Cited by 3